Assertio Holdings (ASRT) Stock Overview
A pharmaceutical company, provides various products to patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ASRT Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Rolvedon And Sympazan Will Create New Market Opportunities
Assertio Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.51 |
| Beta | 0.29 |
| 1 Month Change | 9.72% |
| 3 Month Change | 8.21% |
| 1 Year Change | -49.39% |
| 3 Year Change | -80.57% |
| 5 Year Change | -80.89% |
| Change since IPO | -95.60% |
Recent News & Updates
Assertio Holdings, Inc. (NASDAQ:ASRT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 15
Is Assertio Holdings (NASDAQ:ASRT) Using Too Much Debt?
Apr 30
Rolvedon And Sympazan Will Create New Market Opportunities
Strategic market penetration and increased commercial efforts for Rolvedon and Sympazan aim to boost revenue growth.Recent updates
Assertio Holdings, Inc. (NASDAQ:ASRT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 15Is Assertio Holdings (NASDAQ:ASRT) Using Too Much Debt?
Apr 30Rolvedon And Sympazan Will Create New Market Opportunities
Strategic market penetration and increased commercial efforts for Rolvedon and Sympazan aim to boost revenue growth.Assertio Holdings, Inc.'s (NASDAQ:ASRT) Revenues Are Not Doing Enough For Some Investors
Mar 14Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment?
Dec 24Little Excitement Around Assertio Holdings, Inc.'s (NASDAQ:ASRT) Revenues As Shares Take 25% Pounding
Nov 15Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?
Sep 25Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%
Aug 19There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise
Jul 04Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 07Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?
Apr 18Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified
Mar 13We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt
Apr 26Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?
Mar 02Assertio Holdings Looks Good To Rebound After Recent Price Plunge
Sep 07Assertio Holdings: Substantial Upside
Aug 21Assertio Therapeutics Q2 2022 Earnings Preview
Aug 05Shareholder Returns
| ASRT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.6% | -3.6% | -0.3% |
| 1Y | -49.4% | -7.7% | 15.7% |
Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned -7.4% over the past year.
Return vs Market: ASRT underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| ASRT volatility | |
|---|---|
| ASRT Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ASRT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ASRT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 58 | Brendan O’Grady | www.assertiotx.com |
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.
Assertio Holdings, Inc. Fundamentals Summary
| ASRT fundamental statistics | |
|---|---|
| Market cap | US$68.07m |
| Earnings (TTM) | -US$30.61m |
| Revenue (TTM) | US$119.00m |
Is ASRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASRT income statement (TTM) | |
|---|---|
| Revenue | US$119.00m |
| Cost of Revenue | US$35.84m |
| Gross Profit | US$83.17m |
| Other Expenses | US$113.78m |
| Earnings | -US$30.61m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 69.89% |
| Net Profit Margin | -25.72% |
| Debt/Equity Ratio | 35.9% |
How did ASRT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/30 07:13 |
| End of Day Share Price | 2025/07/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Assertio Holdings, Inc. is covered by 22 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| null null | Argus Research Company |
| Hamed Khorsand | BWS Financial Inc. |